Meningococcal Disease Treatment and Prevention: Ceftriaxone, Vaccines, and Chemoprophylaxis

Meningococcal disease is one of the few bacterial infections that can kill a healthy young person in less than 24 hours. The speed of treatment is the single most important factor determining whether a patient lives, and whether they survive without permanent damage. This page explains the three pillars of treatment — antibiotics, anti-inflammatory steroids, and intensive care — plus how to protect the people around the patient and prevent the disease from striking in the first place.

  1. This Is a Medical Emergency
  2. Antibiotics — Immediate and Urgent
  3. Why Dexamethasone Matters
  4. ICU Care and Monitoring
  5. Chemoprophylaxis — Protecting Household Contacts
  6. Meningococcal Vaccines — the Best Prevention
  7. Who Needs Vaccines Urgently
  8. Managing Long-Term Complications
  9. What to Do If You Are a Household Contact
  10. Key Research Papers
  11. Connections
  12. Featured Videos

This Is a Medical Emergency

Meningococcal disease can move from first symptoms to death in under 24 hours. In children, it can progress even faster — a child who is unwell at breakfast can be in septic shock by noon. There is no time to wait and see.

If meningococcal disease is suspected — a stiff neck, sensitivity to light, a rash that does not fade under pressure, altered consciousness, or sudden severe headache — the single most important action is to give intravenous (IV) ceftriaxone as fast as possible. You do not need to wait for blood results. You do not need to wait for a lumbar puncture. Treat first, confirm later.

The three pillars of treatment are:

Studies have shown that every hour of delay in giving antibiotics significantly increases the risk of death. A delay of even six hours roughly doubles mortality compared with treatment given at presentation.

Antibiotics — Immediate and Urgent

The antibiotic of choice for meningococcal disease is ceftriaxone, a third-generation cephalosporin given intravenously. The standard adult dose is 2 grams every 12 hours. For children, the dose is weight-based.

Ceftriaxone is chosen for three reasons:

If ceftriaxone is unavailable, penicillin G is an acceptable alternative when the organism is known to be penicillin-sensitive. However, because resistance patterns vary and the diagnosis may not yet be confirmed, ceftriaxone remains the safer first choice.

If a patient reports a penicillin allergy, the severity of that allergy matters. A mild skin rash from amoxicillin in childhood is not a contraindication to ceftriaxone. A documented anaphylactic reaction to a penicillin is more concerning, though cross-reactivity between penicillins and third-generation cephalosporins is low (under 2%). In a life-threatening emergency, the risk of withholding antibiotics far outweighs the risk of a cross-reaction.

For detailed dosing regimens, antibiotic duration, and monitoring parameters, see the Antibiotic Treatment sub-article.

Why Dexamethasone Matters

When antibiotics kill meningococcal bacteria, the dying bacteria release large amounts of toxins. The immune system reacts violently, flooding the brain and its surrounding membranes with inflammatory chemicals. This inflammatory surge — not the bacteria themselves — causes much of the permanent damage: hearing loss, brain damage, and increased pressure inside the skull that can herniate the brainstem.

Dexamethasone is a corticosteroid that blunts this inflammatory response. The landmark 2002 New England Journal of Medicine trial by de Gans and van de Beek showed that giving dexamethasone just before or with the first antibiotic dose cut the rate of death from bacterial meningitis by more than half in adults with pneumococcal meningitis, and significantly reduced unfavorable outcomes across all causes of bacterial meningitis.

The timing is critical. Dexamethasone must be given before or simultaneously with the first antibiotic dose. If antibiotics have already been running for several hours, the initial inflammatory surge has already happened. Giving dexamethasone at that point provides little benefit and may suppress the immune response in ways that are no longer helpful.

The standard regimen is dexamethasone 0.15 mg/kg IV every 6 hours for 4 days, starting with the first antibiotic dose. For an average adult, this is typically 10 mg every 6 hours.

Because dexamethasone is most clearly beneficial in pneumococcal meningitis, some guidelines recommend discontinuing it after 24–48 hours if the cause is confirmed as meningococcal. However, in practice, when the diagnosis is not immediately confirmed, most clinicians complete the full 4-day course.

ICU Care and Monitoring

Antibiotics and dexamethasone treat the infection and the inflammatory response, but many patients develop serious complications that require moment-to-moment intensive care management:

For a detailed account of ICU management and monitoring protocols, see the Antibiotic Treatment sub-article.

Chemoprophylaxis — Protecting Household Contacts

Meningococcal bacteria live harmlessly in the back of the throat (nasopharynx) of around 10% of the general population at any given time. Most carriers never get sick. But the bacteria can spread to others through prolonged close contact — living together, sharing the same bed, or kissing.

When a case of meningococcal disease is confirmed, everyone who has had close contact with the patient in the preceding 7 days must receive antibiotic prophylaxis — even if they feel completely well. The purpose is to clear any meningococcal bacteria they may be carrying in their throats before those bacteria can cause disease.

Close contacts who require prophylaxis include:

The preferred antibiotic regimens for prophylaxis are:

Prophylaxis should ideally be given within 24 hours of the index case being identified. After 2 weeks, the benefit is much reduced. Public health departments coordinate the identification and contacting of all close contacts.

For full details on resistance patterns and prophylaxis in special populations, see the Chemoprophylaxis sub-article.

Meningococcal Vaccines — the Best Prevention

Vaccination is far more effective than any treatment — it prevents the disease from occurring in the first place. There are two types of meningococcal vaccine, targeting different serogroups of the bacterium:

MenACWY vaccines

These conjugate vaccines protect against serogroups A, C, W, and Y, which together account for the majority of meningococcal disease in the United States outside of serogroup B. In the US, Menactra and Menveo are the two available MenACWY vaccines. Routine vaccination is recommended at age 11–12, with a booster at age 16.

MenB vaccines

Serogroup B meningococcal disease is not covered by MenACWY vaccines because the group B capsular polysaccharide mimics human tissue and cannot be used as a vaccine antigen. Two MenB vaccines are available in the US: Bexsero and Trumenba. These are recommended for certain high-risk groups (see below) and may be given to adolescents aged 16–23 at the doctor's or patient's discretion.

Travel vaccination

Travelers to sub-Saharan Africa (the "meningitis belt") and pilgrims attending the Hajj in Saudi Arabia are at significantly elevated risk of meningococcal disease. MenACWY vaccination is required for Hajj, and strongly recommended for travelers to the meningitis belt, particularly during the dry season (December to June) when outbreaks are most common.

For detailed vaccine schedules, dosing intervals, and efficacy data, see the Meningococcal Vaccines sub-article.

Who Needs Vaccines Urgently

Some people face dramatically higher risks of meningococcal disease than the general population and should be vaccinated with both MenACWY and MenB vaccines regardless of age, and should receive booster doses throughout their lives:

Managing Long-Term Complications

Many survivors of meningococcal disease face significant long-term consequences. Identifying and managing these early greatly improves outcomes:

Hearing loss

Bacterial meningitis is one of the most common causes of acquired deafness in children. The inflammatory process in the fluid surrounding the brain damages the cochlea — the hearing organ. Damage can occur rapidly during the acute illness. Every patient who has recovered from bacterial meningitis should have a formal audiological assessment before or shortly after hospital discharge. Cochlear implants can restore hearing in children who lose it to meningitis, but the window for implantation narrows as the cochlea can ossify (fill with bone) within weeks of infection.

Limb loss and skin grafting

Severe meningococcemia can destroy tissue in the hands, feet, and legs through DIC and blood vessel inflammation. Some patients — particularly children — require amputation of fingers, toes, or limbs. Rehabilitation is intensive and long-term, involving prosthetics, occupational therapy, and physiotherapy. Skin grafting may be needed where the purpuric rash caused extensive tissue death.

Neurological complications

Brain damage from meningitis can cause cognitive difficulties, memory problems, learning disabilities, and behavioral changes, particularly in children. These may not be apparent immediately after discharge and can emerge over months. Neuropsychological testing and educational support are important follow-up steps.

Psychological impact

Post-traumatic stress disorder is common among meningococcal disease survivors and their families. Parents who watched a child deteriorate rapidly — often in a matter of hours — frequently experience significant psychological distress. Psychological support, including counseling and peer support groups, should be offered as a routine part of follow-up care.

Other complications

Adrenal insufficiency (from Waterhouse-Friderichsen syndrome), chronic renal impairment, arthritis, and eye inflammation (uveitis) can all occur as sequelae of meningococcal disease. Regular review by a specialist familiar with post-meningococcal complications helps identify and manage these.

What to Do If You Are a Household Contact

If someone in your household or someone you have kissed has been diagnosed with meningococcal disease, do not wait to see if you feel unwell. Take these steps immediately:

  1. Contact your GP, local health department, or an emergency clinic today. Tell them you have been identified as a close contact of a confirmed meningococcal case. They will arrange antibiotic prophylaxis for you, usually within 24 hours.
  2. Get the antibiotic prophylaxis. Even if you feel completely well, take the full course or dose. You may be carrying the bacteria in your throat without any symptoms at all.
  3. Get vaccinated if you have not been vaccinated recently or if your vaccines are not up to date. Prophylactic antibiotics clear current carriage, but they do not protect you from future exposure. Vaccination does.
  4. Monitor yourself and family members closely for 10 days after exposure. Secondary cases — while uncommon — can occur. Know the warning signs: sudden high fever, severe headache, stiff neck, sensitivity to light, a rash that does not fade when pressed with a glass (the "glass test"). If any of these appear, call emergency services immediately — do not drive yourself to the hospital.
  5. Do not share the story publicly in ways that identify the patient without their consent. Public health departments will handle formal notification of other contacts in a controlled way.

The risk to a household contact who receives prophylaxis is very low. The antibiotic clears nasopharyngeal carriage reliably in over 90% of cases. The greater risk is to contacts who are not identified and do not receive prophylaxis.

Key Research Papers

  1. Tunkel AR, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis. 2004;39(9):1267–84. PMID 15494903
  2. de Gans J, van de Beek D. Dexamethasone in adults with bacterial meningitis. N Engl J Med. 2002;347(20):1549–56. PMID 12432041
  3. Proulx N, et al. Delays in the administration of antibiotics are associated with mortality from adult acute bacterial meningitis. QJM. 2005;98(4):291–8. PMID 15760921
  4. Brouwer MC, Tunkel AR, van de Beek D. Epidemiology, diagnosis, and antimicrobial treatment of acute bacterial meningitis. Clin Microbiol Rev. 2010;23(3):467–492. PMID 20610819
  5. Stephens DS, et al. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet. 2007;369(9580):2196–2210. PMID 17604802
  6. Rosenstein NE, et al. Meningococcal disease. N Engl J Med. 2001;344(18):1378–1388. PMID 11333996
  7. Cohn AC, et al. Prevention and control of meningococcal disease: recommendations of ACIP. MMWR Recomm Rep. 2013;62(RR-2):1–28. PMID 23445929
  8. Tan LK, Carlone GM, Borrow R. Advances in the development of vaccines against Neisseria meningitidis. N Engl J Med. 2010;362(16):1511–20. PMID 20410516
  9. Edmond K, et al. Global and regional risk of disabling sequelae from bacterial meningitis. Lancet Infect Dis. 2010;10(5):317–28. PMID 20417414
  10. Zalmanovici Trestioreanu A, et al. Antibiotics for preventing meningococcal infections. Cochrane Database Syst Rev. 2011;(8):CD004785. PMID 21833946
  11. Welch SB, Nadel S. Treatment of meningococcal infection. Arch Dis Child. 2003;88(7):608–14. PMID 12818909

Back to Table of Contents

Connections

Back to Table of Contents